Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APL-1400
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Peptides
- Administration
- Ophthalmic
01
Overview
APL-1400 is an investigational, long-acting formulation of the complement component 3 (C3) inhibitor pegcetacoplan, developed by Apellis Pharmaceuticals (acquired by Biogen). It is designed as a sustained-release delivery system, such as an intravitreal implant or a highly concentrated solution, to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). By inhibiting C3, the drug prevents the activation of the complement cascade, thereby reducing the inflammatory processes that drive the progression of retinal lesions. APL-1400 aims to significantly extend the interval between treatments compared to the monthly or bi-monthly dosing required for the first-generation product, SYFOVRE, thereby reducing the treatment burden for patients and improving long-term compliance.
02
Targets
C3
Beyond the preview
Go deeper on APL-1400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APL-1400.